Abstract
Clinical trials with cytokine inhibitors have failed to show efficacy and confirm preclinical findings in sepsis and systemic inflammatory response syndromes. However, a better understanding of the pathogenesis of sepsis syndrome, and of proinflammatory cytokine signal transduction pathways, including the role of nuclear factor kappa B and inflammation-induced apoptosis, have provided new therapeutic opportunities for cytokine and anticytokine therapies.
Publication types
-
Research Support, U.S. Gov't, P.H.S.
-
Review
MeSH terms
-
Clinical Trials as Topic
-
Cytokines / antagonists & inhibitors
-
Cytokines / physiology*
-
Cytokines / therapeutic use
-
Humans
-
Inflammation / physiopathology*
-
Inflammation / therapy*
-
NF-kappa B / metabolism
-
Sepsis / immunology
-
Sepsis / physiopathology*
-
Sepsis / therapy
-
Signal Transduction
-
Stress, Physiological / physiopathology*
-
Syndrome
-
Tumor Necrosis Factor-alpha / physiology
Substances
-
Cytokines
-
NF-kappa B
-
Tumor Necrosis Factor-alpha